Shares of Bristol-Myers Squibb Co (NYSE:BMY) ended Thursday session in green amid volatile trading. The shares closed up +0.49 points or 0.88% at $56.42 with 10.61 million shares getting traded. Post opening the session at $56.03, the shares hit an intraday low of $55.87 and an intraday high of $56.65 and the price vacillated in this range throughout the day. The company has a market cap of $94.90 billion and the numbers of outstanding shares have been calculated to be 1.66 billion shares.
Bristol-Myers Squibb Co (BMY) will take part in Leerink Partners Immuno-Oncology Roundtable Conference on Thursday, September 29, 2016, in New York. Fouad Namouni, senior vice president, Head of Oncology, will answer questions about the company at 3:00 p.m. EDT.
Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.
Shares of Boston Scientific Corporation (NYSE:BSX) ended Thursday session at $23.73 with 9.68 million shares getting traded. Post opening the session at $23.83, the shares hit an intraday low of $23.47 and an intraday high of $23.89 and the price vacillated in this range throughout the day. The company has a market cap of $32.87 billion and the numbers of outstanding shares have been calculated to be 1.36 billion shares.
Boston Scientific Corporation (BSX) on Sept. 19, 2016 received CE Mark for the LOTUS Edge™ Valve System, the company’s next generation transcatheter aortic valve implantation (TAVI) technology. The LOTUS Edge valve system is indicated for aortic valve replacement in patients with severe aortic stenosis who are considered at high risk for surgical valve replacement. Instead of open heart surgery, the replacement valve is delivered via transcatheter percutaneous delivery, a minimally invasive procedure involving a small incision to gain access to a blood vessel.
In comparison to the Lotus™ Valve System, this next iteration incorporates a more flexible, lower profile catheter designed to improve ease of use and accommodate tortuous anatomy. Another differentiating feature of the LOTUS Edge valve system is the inclusion of Depth Guard™, a design element intended to reduce the need for a permanent pacemaker (PPM).
“The LOTUS Edge device is a highly anticipated next generation of the Lotus Valve System,” said Professor Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia. “It retains many of its predecessor’s unique and valuable proprietary features, including the ability to reposition the device precisely and prevent paravalvular leak, while incorporating new design characteristics such as a more flexible catheter for easier delivery and Depth Guard™ technology designed to reduce valve interaction with the conduction system of the heart during valve deployment.”